Travere Therapeutics (NASDAQ:TVTX) EVP Peter Heerma Sells 172,717 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) EVP Peter Heerma sold 172,717 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $63.43, for a total transaction of $10,955,439.31. Following the completion of the transaction, the executive vice president directly owned 117,066 shares in the company, valued at $7,425,496.38. This represents a 59.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Peter Heerma also recently made the following trade(s):

• On Thursday, September 17th, Peter Heerma sold 8,282 shares of Travere Therapeutics stock. The stock was sold at an average price of $65.07, for a total value of $538,909.74.
• On Tuesday, September 15th, Peter Heerma sold 102,190 shares of Travere Therapeutics stock. The stock was sold at an average price of $62.26, for a total value of $6,362,349.40.

Travere Therapeutics Price Performance

Shares of Travere Therapeutics stock opened at $64.74 on Friday. The business has a 50 day simple moving average of $61.63 and a two-hundred day simple moving average of $48.50. Travere Therapeutics, Inc. has a 12 month low of $22.06 and a 12 month high of $68.73. The stock has a market capitalization of $6.10 billion, a P/E ratio of -140.74 and a beta of 1.05. The company has a debt-to-equity ratio of 24.58, a current ratio of 4.05 and a quick ratio of 3.99.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%.The firm had revenue of $169.58 million for the quarter, compared to analyst estimates of $157.27 million. During the same period in the previous year, the company posted $0.13 earnings per share. The business’s revenue was up 48.2% on a year-over-year basis. As a group, analysts predict that Travere Therapeutics, Inc. will post -0.54 EPS for the current fiscal year.

Key Stories Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Brokerages have assigned Travere Therapeutics a consensus rating of “Moderate Buy,” indicating that analysts generally continue to see upside potential in the stock. Travere Therapeutics Given Consensus Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on Travere’s rare-disease pipeline and commercial outlook, but no new operating information was announced. Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
• Negative Sentiment: Multiple insiders, including the CEO, CFO, CAO and EVPs, reduced their holdings, with individual ownership declines ranging from about 7% to 60%. Although the sales were prearranged, concentrated insider selling may raise questions about near-term sentiment and limit the stock’s momentum.

Hedge Funds Weigh In On Travere Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC acquired a new stake in shares of Travere Therapeutics in the 2nd quarter worth $70,000. JW Asset Management LLC purchased a new position in shares of Travere Therapeutics during the 2nd quarter worth $1,704,000. Nykredit A S acquired a new position in shares of Travere Therapeutics during the 2nd quarter valued at about $237,000. Allianz Asset Management GmbH acquired a new position in shares of Travere Therapeutics during the 2nd quarter valued at about $2,441,000. Finally, Corient Private Wealth LP grew its holdings in shares of Travere Therapeutics by 1.4% in the second quarter. Corient Private Wealth LP now owns 48,125 shares of the company’s stock valued at $2,734,000 after purchasing an additional 648 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on TVTX shares. Weiss Ratings lowered shares of Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. HC Wainwright raised their price target on shares of Travere Therapeutics from $57.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. TD Cowen boosted their price target on shares of Travere Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group upped their price objective on shares of Travere Therapeutics from $62.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Evercore set a $78.00 price objective on shares of Travere Therapeutics in a research note on Monday, August 10th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $68.00.

About Travere Therapeutics

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.